

1. Sales January to March 2006 and 2005

	2006	2005	% change	
	CHF m	CHF m	In CHF	In local currencies
Pharmaceuticals Division	7,739	6,155	+26	+19
Roche Pharmaceuticals	4,821	3,859	+25	+19
Genentech	2,056	1,341	+53	+40
Chugai	862	955	-10	-8
Diagnostics Division	2,091	1,935	+8	+3
Roche Group	9,830	8,090	+22	+15

2. Quarterly local sales growth by Division in 2005 and 2006

	Q2 2005 vs. Q2 2004	Q3 2005 vs. Q3 2004	Q4 2005 vs. Q4 2004	Q1 2006 vs. Q1 2005
Pharmaceuticals Division	+21	+21	+34	+19
Roche Pharmaceuticals	+18	+17	+32	+19
Genentech	+41	+42	+49	+40
Chugai	+8	+7	+22	-8
Diagnostics Division	+4	+6	+3	+3
Roche Group	+17	+17	+26	+15

3. Quarterly sales by Division in 2005 and 2006

CHF millions	Q1 2005	Q2 2005	Q3 2005	Q4 2005	Q1 2006
Pharmaceuticals Division	6,155	6,497	6,782	7,834	7,739
Roche Pharmaceuticals	3,859	4,119	4,191	4,786	4,821
Genentech	1,341	1,526	1,765	1,982	2,056
Chugai	955	852	826	1,066	862
Diagnostics Division	1,935	2,035	2,038	2,235	2,091
Roche Group	8,090	8,532	8,820	10,069	9,830

4. Top 20 Pharmaceuticals Division product sales¹ and local growth² in Q1 2006: US, Japan and Europe/Rest of World

	Total		US		Japan		Europe/RoW	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%
MabThera/Rituxan	1,146	16%	634	7%	41	3%	471	30%
Herceptin	861	107%	375	123%	32	31%	454	105%
Avastin	676	141%	516	96%	-	-	160	654%
Tamiflu	601	37%	168	414%	170	-33%	263	88%
NeoRecormon/Epogin	535	3%	-	-	160	-3%	375	6%
CellCept	454	15%	221	32%	7	15%	226	2%
Pegasys	350	2%	103	-14%	17	-11%	230	12%
Xeloda	238	35%	92	40%	6	1%	140	34%
Xenical	181	16%	34	24%	-	-	147	14%
Tarceva	172	182%	120	95%	-	-	52	-
Kytril	130	18%	57	31%	29	6%	44	13%
Xolair	124	39%	124	39%	-	-	-	-
Nutropin	118	-3%	114	-3%	-	-	4	12%
Cymevene/Valcyte	110	21%	55	15%	-	-	55	27%
Rocephin	110	-69%	9	-96%	13	-11%	88	-24%
Pulmozyme	109	14%	64	12%	-	-	45	18%
Neutrogen	93	19%	-	-	93	19%	-	-
Activase/TNKase	88	19%	78	19%	-	-	10	14%
Dilatrend	81	-6%	-	-	-	-	81	-6%
Bonviva/Boniva	75	-	69	-	-	-	6	-
New products not covered in Top 20								
Fuzeon	72	36%	33	14%	-	-	39	60%
Copegus	60	-43%	6	-88%	-	-	54	-11%
Raptiva	31	-1%	31	-1%	-	-	-	-
Evista	27	76%	-	-	27	76%	-	-
Renagel	13	20%	-	-	13	20%	-	-
Actemra	1	-	-	-	1	-	-	-

¹ Roche Pharmaceuticals, Genentech and Chugai combined

² versus Q1 2005

5. Top 20 Pharmaceuticals Division quarterly local product sales growth¹ in 2005 and 2006

	Q2 2005 vs. Q2 2004	Q3 2005 vs. Q3 2004	Q4 2005 vs. Q4 2004	Q1 2006 vs. Q1 2005
MabThera/Rituxan	23%	18%	23%	16%
Herceptin	31%	57%	77%	107%
Avastin	112%	107%	127%	141%
Tamiflu	707%	148%	631%	37%
NeoRecormon/Epogin	8%	6%	12%	3%
CellCept	25%	28%	25%	15%
Pegasys	22%	15%	17%	2%
Xeloda	50%	44%	47%	35%
Xenical	0%	9%	9%	16%
Tarceva	-	-	722%	182%
Kytril	18%	14%	5%	18%
Xolair	88%	51%	57%	39%
Nutropin	10%	3%	4%	-3%
Cymevene/Valcyte	29%	22%	23%	21%
Rocephin	-5%	-54%	-55%	-69%
Pulmozyme	20%	15%	15%	14%
Neutrogen	13%	20%	18%	19%
Activase/TNKase	3%	9%	23%	19%
Dilatrend	-13%	-12%	3%	-6%
Bonviva/Boniva	-	-	-	-

¹ Roche Pharmaceuticals, Genentech and Chugai combined

6. Pharmaceuticals Division quarterly local product sales growth¹ US in 2005 and 2006

	Q2 2005 vs. Q2 2004	Q3 2005 vs. Q3 2004	Q4 2005 vs. Q4 2004	Q1 2006 vs. Q1 2005
MabThera/Rituxan	16%	14%	20%	7%
Herceptin	29%	70%	99%	123%
Avastin	85%	78%	88%	96%
Tamiflu	493%	132%	390%	414%
NeoRecormon/Epogin	-	-	-	-
CellCept	33%	52%	44%	32%
Pegasys	19%	9%	14%	-14%
Xeloda	72%	51%	64%	40%
Xenical	-14%	20%	18%	24%
Tarceva	-	-	528%	95%
Kytril	33%	20%	-2%	31%
Xolair	88%	51%	57%	39%
Nutropin	10%	3%	4%	-3%
Cymevene/Valcyte	20%	17%	14%	15%
Rocephin	5%	-75%	-81%	-96%
Pulmozyme	28%	17%	15%	12%
Neutrogen	-	-	-	-
Activase/TNKase	5%	10%	25%	19%
Dilatrend	-	-	-	-
Bonviva/Boniva	-	-	-	-

¹ Roche Pharmaceuticals and Genentech combined

7. Pharmaceuticals Division quarterly local product sales growth Japan¹ in 2005 and 2006

	Q2 2005 vs. Q2 2004	Q3 2005 vs. Q3 2004	Q4 2005 vs. Q4 2004	Q1 2006 vs. Q1 2005
MabThera/Rituxan	11%	1%	5%	3%
Herceptin	18%	15%	26%	31%
Avastin	-	-	-	-
Tamiflu	-	-	733%	-33%
NeoRecormon/Epogin	5%	2%	7%	-3%
CellCept	26%	18%	22%	15%
Pegasys	33%	4%	3%	-11%
Xeloda	38%	27%	20%	1%
Xenical	-	-	-	-
Tarceva	-	-	-	-
Kytril	10%	10%	11%	6%
Xolair	-	-	-	-
Nutropin	-	-	-	-
Cymevene/Valcyte	-	-	-	-
Rocephin	13%	17%	14%	-11%
Pulmozyme	-	-	-	-
Neutrogen	13%	20%	18%	19%
Activase/TNKase	-	-	-	-
Dilatrend	-	-	-	-
Bonviva/Boniva	-	-	-	-

¹ Chugai

8. Pharmaceuticals Division quarterly local product sales growth Europe/Rest of World¹ in 2005 and 2006

	Q2 2005 vs. Q2 2004	Q3 2005 vs. Q3 2004	Q4 2005 vs. Q4 2004	Q1 2006 vs. Q1 2005
MabThera/Rituxan	39%	29%	32%	30%
Herceptin	34%	51%	69%	105%
Avastin	-	1755%	1203%	654%
Tamiflu	654%	158%	864%	88%
NeoRecormon/Epogin	10%	9%	16%	6%
CellCept	19%	9%	9%	2%
Pegasys	23%	20%	23%	12%
Xeloda	39%	41%	37%	34%
Xenical	3%	7%	7%	14%
Tarceva	-	-	-	-
Kytril	10%	9%	9%	13%
Xolair	-	-	-	-
Nutropin	-3%	-6%	-5%	12%
Cymevene/Valcyte	39%	27%	36%	27%
Rocephin	-22%	-23%	-10%	-24%
Pulmozyme	10%	11%	16%	18%
Neutrogen	-	-	-	-
Activase/TNKase	-11%	6%	6%	14%
Dilatrend	-13%	-12%	3%	-6%
Bonviva/Boniva	-	-	-	-

¹ Roche Pharmaceuticals

9. Top Pharmaceuticals Division quarterly product sales¹ in 2005 and 2006

CHF millions	Q1 2005	Q2 2005	Q3 2005	Q4 2005	Q1 2006
MabThera/Rituxan	929	1,015	1,057	1,153	1,146
Herceptin	391	460	591	704	861
Avastin	260	347	486	572	676
Tamiflu	424	156	279	699	601
NeoRecormon/Epogin	516	570	564	602	535
CellCept	370	430	441	464	454
Pegasys	325	355	350	373	350
Xeloda	165	190	213	228	238
Xenical	147	165	162	161	181
Tarceva	57	88	101	141	172
Kytril	105	130	130	135	130
Xolair	81	100	104	123	124
Nutropin	110	122	116	128	118
Cymevene/Valcyte	86	99	100	109	110
Rocephin	330	284	152	161	110
Pulmozyme	89	97	100	107	109
Neutrogen	80	89	97	98	93
Activase/TNKase	67	72	84	87	88
Dilatrend	83	84	79	80	81
Bonviva/Boniva	-	21	14	51	75
New products not covered in Top 20					
Fuzeon	50	66	62	81	72
Copegus	104	109	107	87	60
Raptiva	28	31	28	30	31
Evista	16	25	28	35	27
Renagel	11	15	15	16	13
Actemra	-	-	-	1	1

¹ Roche Pharmaceuticals, Genentech and Chugai combined

10. Pharmaceuticals Division quarterly product sales¹ in US in 2005 and 2006

CHF millions	Q1 2005	Q2 2005	Q3 2005	Q4 2005	Q1 2006
MabThera/Rituxan	540	573	612	672	634
Herceptin	153	186	271	321	375
Avastin	240	300	409	462	516
Tamiflu	30	44	109	210	168
NeoRecormon/Epogin	-	-	-	-	-
CellCept	152	200	225	244	221
Pegasys	109	124	124	137	103
Xeloda	60	71	83	99	92
Xenical	25	24	24	26	34
Tarceva	56	86	92	108	120
Kytril	39	54	54	56	57
Xolair	81	100	104	123	124
Nutropin	107	119	113	124	114
Cymevene/Valcyte	43	49	53	57	55
Rocephin	208	180	54	48	9
Pulmozyme	52	57	60	63	64
Neutrogen	-	-	-	-	-
Activase/TNKase	60	64	73	77	78
Dilatrend	-	-	-	-	-
Bonviva/Boniva	-	21	13	48	69
New products not covered in Top 20					
Fuzeon	26	29	34	44	33
Copegus	43	53	53	35	6
Raptiva	28	31	28	30	31
Evista	-	-	-	-	-
Renagel	-	-	-	-	-
Actemra	-	-	-	-	-

¹ Roche Pharmaceuticals and Genentech combined

11. Pharmaceuticals Division quarterly product sales¹ in Japan in 2005 and 2006

CHF millions	Q1 2005	Q2 2005	Q3 2005	Q4 2005	Q1 2006
MabThera/Rituxan	40	52	50	59	41
Herceptin	25	31	32	38	32
Avastin	-	-	-	-	-
Tamiflu	260	3	2	133	170
NeoRecormon/Epogin	168	209	203	232	160
CellCept	6	7	7	9	7
Pegasys	19	23	23	25	17
Xeloda	6	8	8	8	6
Xenical	-	-	-	-	-
Tarceva	-	-	-	-	-
Kytril	28	35	35	40	29
Xolair	-	-	-	-	-
Nutropin	-	-	-	-	-
Cymevene/Valcyte	-	-	-	-	-
Rocephin	15	15	14	17	13
Pulmozyme	-	-	-	-	-
Neutrogen	80	89	97	98	93
Activase/TNKase	-	-	-	-	-
Dilatrend	-	-	-	-	-
Bonviva/Boniva	-	-	-	-	-
New products not covered in Top 20					
Fuzeon	-	-	-	-	-
Copegus	-	-	-	-	-
Raptiva	-	-	-	-	-
Evista	16	25	28	35	27
Renagel	11	15	15	16	13
Actemra	-	-	-	1	1

¹ Chugai

12. Pharmaceuticals Division quarterly product sales in Europe/Rest of World¹ in 2005 and 2006

CHF millions	Q1 2005	Q2 2005	Q3 2005	Q4 2005	Q1 2006
MabThera/Rituxan	349	390	395	422	471
Herceptin	213	243	288	345	454
Avastin	20	47	77	110	160
Tamiflu	134	109	168	356	263
NeoRecormon/Epogin	348	361	361	370	375
CellCept	212	223	209	211	226
Pegasys	197	208	203	211	230
Xeloda	99	111	122	121	140
Xenical	122	141	138	135	147
Tarceva	1	2	9	33	52
Kytril	38	41	41	39	44
Xolair	-	-	-	-	-
Nutropin	3	3	3	4	4
Cymevene/Valcyte	43	50	47	52	55
Rocephin	107	89	84	96	88
Pulmozyme	37	40	40	44	45
Neutrogen	-	-	-	-	-
Activase/TNKase	7	8	11	10	10
Dilatrend	83	84	79	80	81
Bonviva/Boniva	-	-	1	3	6
New products not covered in Top 20					
Fuzeon	24	37	28	37	39
Copegus	61	56	54	52	54
Raptiva	-	-	-	-	-
Evista	-	-	-	-	-
Renagel	-	-	-	-	-
Actemra	-	-	-	-	-

¹ Roche Pharmaceuticals